NanoString Technologies
Current and Future Treatment Decisions for Early Breast Cancer: Clinical Relevance of Molecular Profiling with Prosigna® Gene Signature Assay

Chair: Michael Gnant, Austria

 Intruduction

 Michael Gnant, Austria

 Development and Validation of Intrinsic Subtyping for the Clinic

 Charles M. Perou, USA

 Value of Prosigna® genomic signature for management of early breast cancer

 Nadia Harbeck, Germany

Near the patient innovation: Prosigna® decentralized testing in cancer centers network, and beyond

Frederique Penault-Llorca, France